In the present study, intra-DRN administration of anti-nesfatin-1/NUCB2 alleviated visceral hypersensitivity in MS model rats, accompanied by decreased 5-HT and TPH immunoreactivity in the DRN as compared with vehicle controls. Here, TPH1 is linked to myeloid sarcoma.